Metal–5-Fluorouracil–Histamine Complexes: Solution, Structural,
and Antitumour Studies by Tyagi, Sadhna et al.
Metal BasedDrugs Vol. 8, No. 6, 2002
METAL-5-FLUOROURACIL-HISTAMINE COMPLEXES:
SOLUTION, STRUCTURAL, AND ANTITUMOUR STUDIES
Sadhna Tyagi, Sukh Mahendra Singh, Sujan Gencaslan3,
W.S. Sheldrick
3 and Udai P. Singh*
Department ofChemistry, Indian Institute ofTechnology Roorkee, Roorkee- 247 667, India
2School ofBiotechnology, Banaras Hindu University, Varanasi- 221 005, India
Lehrstuhl fiir Analytische Chemie, Ruhr-Universitt Bochum, D-44801 Bochum, Germany
ABSTRACT
Solution studies were performed pH-metrically to study the interaction of Co(II), Ni(II), Cu(II), Zn(II) and
Cd(II) metal ions with 5-fluorouracil (5FU) and histamine (Hm) separately (binary) and in the presence of
each other (ternary) at 25 + 0.1 C temperature and a constant ionic strength of 0.1 M NaNO3 in aqueous
solution. The ternary complexes have been found to be more stable than the corresponding binary complexes
as shown by the positive value of AlogK. The species distribution curves have been obtained using the
computer programme BEST. On the basis of species distribution results, efforts were also made to prepare
some mixed complexes of Co(II), Ni(II), Cu(II), Zn(II) and Cd(II) ions by performing the reaction of their
metal nitrates, 5FU and Hm in aqueous ethanol medium at suitable pH. The isolated solid complexes were
characterized by different physico-chemical method in order to suggest the possible binding site of the
ligands and the structure of the resultant complexes. All these complexes were checked for their antitumour
activity by injecting in Dalton’s lymphoma (DL) and Sarcoma-180 (S-180) bearing C3H/He mice. The results
indicate that some complexes have good antitumour activity both in vivo and in vitro.
INTRODUCTION
5-Fluorouracil (5FU), a mono fluorinated product of uracil, has entirely different biological properties than
uracil [1]. Since the time of its synthesis, 5FU has been increasingly employed alone or in combination with
other cytotoxic drugs and hormones in the medical treatment of solid tumours. It has also been used in the
treatment of breast, lung, ovary and cervix carcinomas [2]. The antitumour properties of 5FU against
different tumour systems has also been found to be significantly enhanced by the co-administration of
guanosine (in any combination) resulting in therapeutic synergism [3]. The mechanism of action of 5FU is
not well known. In 1986, Joshi et al. [4] suggested that the 5FU is anabolised to 5-fluoro-2"-dexoyuridylic
acid, a potent competitive inhibitor of thymidylate synthetase, and the enzyme which normally converts 2"-
deoxyuridylic acid to thymidylic acid as essential component ofDNA. This is due to the presence of fluorine
atom at the critical C-5 position. Since 5FU and its anabolites are concentrated in cancer cells, this enzymatic
blockade inhibits tumour growth by causing thymineless death of neoplastic cells. Histamine (Hm), a
decarboxylated product of histidine, is a potent vasodilator and is released in certain tissue as a result of
allergic hypersensitivity or inflammation. Histamine also plays an important role in diseases.
The antitumour properties of 5FU and scanty information on its metal complexes in combination with
histamine as antitumour agent encouraged to undertake solution, solid and antitumour activity studies of
5FU-Histamine mixed complexes.
Although several workers have reported the antitumor properties of 5FU and its metal complexes [5], also the
solution studies on 5FU [6] and histamine separately [7], the work on the chemotherapeutic properties of
5FU-histamine metal complexes is not available in the literature.
F
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Fig. 1. Structures of 5-fluorouracil and histamine.
The present paper reports the solution, structural and antitumour studies of Co(II), Ni(II), Cu(II), Zn(II) and
Cd(ll) complexes with 5-fluorouracil (5FU) as one ligand, and histamine (Hm) as another ligand.
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RESULT AND DISCUSSION
Solution studies
The pH-metric titration curves (Figure 2a-e) were plotted as pH vs. a_ (where _a is the number of moles of
alkali required per mole of the ligand) for 5FU (curve a), M-5FU (curve b), Hm (curve c), M-Hrn (curve d)
and M-5FU-Hm (curve e) systems. The deprotonation constant values (pKn) and various formation censtants
for binary and ternary systems (Table 1) were calculated by using the literature method [8] and the computer
programs pKAS and BEST [9] respectively. From the ligand curves a and c, the first proton dissociation
constant (pK0 values for 5FU and Hm are calculated to be 7.55+0.06 and 6.20-0.06 by considering the first
deprotonation equilibrium HzL H
+ + HL and computer program pKAS [9]. Similarly, the second
deprotonation HL" IT + Lz constant (pK2) values are also evaluated to be 10.60+0.03 and 9.85+0.04 for
the two ligands, respectively.
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Fig. 2. pH metric titration curves of (a) 5-fluorouracil solution ( 1.0 mM), (b) metal ion (1.0 mM) + [a], (c)
histamine (1.0 mM), (d) metal ion (1.0 mM) + [c], (e) metal ion (1.0 mM) + [a] + [c] at T-- 25 + 0.1 C and t
0.1 M (NaNO3) in aqueous solution. Where a is number ofmole of alkali per mole of ligand.
In Fig. 2, the titration curves b and d account for the association of metal ions with 5FU (curve b) and Hm
(curve d), respectively. The overall stability constant for each binary system, M-5FU as well as M-Hm was
evaluated by using the method described earlier [8] and the BEST computer programme [9].
The order of stability of 1:1 binary system of 5FU and Hm is Co(II)<Ni(lI)<Cu(II)>Zn(II)>Cd(lI), which is
in conformity with Irving-William’s order. Although the Cu(II) complexes should have higher stability as
compare to the Co(II) and Ni(II) complexes but it has been found to be unusually higher than could be
expected from the ionic radii and electronegativity considerations. It may be attributed to the unique
electronic configuration (d9) of the Cu(II) ion which is capable of additional stabilization due to the Jahn-
Teller distortion [10]. In addition to this, the Hm molecule is supposed to be the more basic than 5FU, hence
M(II)-Hm systems should be more stable than the corresponding M(II)-5FU systems, which is also supported
from the results presented in Table 1. It may be due to the binding nature ofHm as it binds with metal ions
through both the imidazole and amine groups produce a chelate ring that enhances the stability of metal
complexes of Hm. The titration curve clearly exhibits the interaction of 5FU and Hm with metal ions in the
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presence of each other. The stability constants of various ternary metal-ligand systems were evaluated by
using a previous method [8] and the BEST computer programme [9] (Table 1). The overall stability constants
of the binary and the corresponding ternary metal-ligand complexes were compared and it has been found
that the ternary complexes are more stable than the metal-5FU complexes but are less stable than the
corresponding metal-Hm complexes. It may be due to higher concentration of the electrons around the [M-
5FU]
+ system in comparison to the [M(H20),]
2+ system hence statistical steric and electrostatic factors lead to
lower stability constants ofternary system than the binary system of Hm in solution.
Table 1. Overall stability constants (log K)
a of binary (1:1) and ternary (1:1:1) metal-ligand complexes
formed in aqueous solution at T 25 + 0.1 C and la 0.1 M NaNO3
Metal M:5FU M:Hm M:5FU:Hm AlogK
Ions logKff4 IOgKM IOgKM
(a) (b) (a) (b) (a) (b) (a) (b)
Co(II) 5.08+0.15 5.91 6.21+0.15 8.37 5.31+0.03 5.25 -0.90 -3.12
Ni(II) 5.91+/-0.06 5.32 7.38+/-0.09 8.86 5.99+/-0.06 5.44 1.39 -3.42
Cu(II) 8.12+/-0.07 8.22 9.74+/-0.14 10.24 8.28+/-0.07 7.88 -1.46 -2.36
Zn(II) 6.11+/-0.15 8.01 6.43+/-0.17 8.32 6.32+/-0.14 6.23 -0.11 -2.09
Cd(II) 5.76+/-0.09 6.02 6.02+/-0.13 7.90 5.93+/-0.09 5.85 -0.09 -2.05
aDeviation (3o) range in between +/-0.06 to 0.18.
Method (a) Interpolation ofHalfn values; (b) Average value method
AlogK: Difference between the stability constant ofternary complex and binary complex ofsecondary ligand.
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Fig. 3. Species distribution curve ofZn(II):5-fluorouracil:histamine (1" 1" 1) ternary system.
The species distribution for various possible species in solution has been performed for all the metal ions
reported in the present work and the species distribution plot for Zn(II)-5FU-Hm has been given in Fig. 3 as
representative graph. Fig. 3 indicates the presence of free metal and 1"1 neutral complex of M-5FU in
solution around pH 2.0. Their concentration start decreases with increase of the concentration of neutral
species of M-Hm and M-5FU-Hm and attain almost a zero value at higher pH range. From the species
distribution curve it can be stated further that the hydroxo species of ternary complex predominate the neutral
species (i.e. 100% at pH 10.0) being formed comparatively in small amounts in the lower pH range under
investigation. Again formation of (1:1) neutral species suggests the bidentate nature of both the ligand in
binary system. Same pattern of species distribution occurs in the ternary system of other metal ions. At pH
2.0, free metals are present in 73% to 91% amount. Association of 5FU with each metal ions start at very low
pH range (- 2.0) resulting in the formation of M-5FU species in which metal ions distributed as: 12% for
Co(II), Cu(II) and Zn(II); 8.5% in Cd(II) and 24% in Ni(II).
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Table 2. Analytical data ofthe complexes
Amount Found (Calc.) (%)
Complex Color M C H N
Melting
Point
(c)
Co(5FU)(Hm)(OH).2HO
Ni(5FU)(Hm)(OH).2HzO
Cu(5FU)(Hm)(OH).2H:O
Zn(5FU)(Hm)(OH).2H20
Cd(5FU)(Hm)(OH).2HzO
Light Pink 16.55 30.91 03.69 20.05 >300
(16.69) (30.61) (03.42) (19.80)
Green 16.54 30.04 03.36 19.37 290
(16.64) (30.63) (03.43) (19.84)
Intense Green 17.63 30.47 03.48 19.67 180
(17.76) (30.22) (03.38) (19.58)
White 18.05 30.48 03.42 19.55 >300
(18.18) (30.06) (03.36) (19.48)
White 28.81 27.76 03.03 17.42 >300
(27.65) (26.59) (02.97) (17.22)
Furthermore association ofHm with each metal ions and M-5FU start at pH range (i.e. 3.0) resulting in the
formation ofM-Hm and M-5FU-Hm species are as: 61% 72% for Cd(II), Co(II) and Zn(II) at pH 5.0;
78% for Cu(II) at pH- 4.0; 46% for Ni(II) at pH- 5.0 and 11% 28% for Cd(II), Co(II) and Zn(II) at
pH 5.0; 13% for Cu(II) at pH 3.0; 38% for Ni(II) at pH 4.0 respectively. Finally the total metal
distributed into ML, MA and MLA species get converted into the hydroxo species (MLA(OH)) at higher pH
(i.e. > 8.0) and the metal ion distribution observed in about 100% at the corresponding pH. Again species
distribution data clearly show that the ternary complexes are less stable than binary complexes of secondary
ligand.
All the isolated mixed ligand complexes are colored except those of Zn(II) and Cd(II) and involve 1:1:1
metal to 5FU to Hm ratio (where M Co(II), Ni(II), Cu(II), Zn(II) or Cd(II)). Most of the complexes do not
melt up to 300C as reported in Table 2.
Infrared studies
The infrared spectrum of 5FU is reported in the literature [5a] and IR band assignments for histamine have
been made by comparing its spectrum with various amino acids reported in the literature [11-13]. Table 3
records some important infrared data for the ligands and their mixed complexes. Histamine molecule is
potentially a bidentate and forms complex with bivalent cations through the imidazole nitrogen and the amino
nitrogen. The neutral imidazolyl group of Hm exists in tautomeric equilibrium between Nl-protonated form
and the N3-protonated one. Either one of the unprotonated imidazole nitrogens of these tautomers can
participate in coordination to metal ions. Basically histamine molecule has three coordinating sites viz. N1, N3
imidazole nitrogen and amino nitrogen. As reported in the literature [11-13], it is sterically impossible for a
Hm molecule to make a chelate ring with metal ions through N atom and amino nitrogen. This means that
when Hm molecule will coordinate through N1 imidazole atom, its amino group will exist in the free and
NH3
+ state. The imidazole nitrogen ofHm can also form hydrogen bonds. Infrared spectra of the complexes
(Table 3) show shift in NH3
+ bands of Hm (3110 cm"l) either toward lower frequency side or toward higher
frequency side on coordination. The shifting of vN-H band as compared to that in free Hm (3310 cml)
suggest the coordination ofHm throu.h
the nitrogen of amino group. This is further supported by the shill in
the VCT-N band appearing at 1036 cm in free Hm.
The band observed at 1570 cm
-l and 1252 cm
l in the spectrum ofHm can be assigned to the imidazole ring
vibration ofHm for N3 and amino nitrogen. On coordination the imidazole ring vibration shifts toward lower
or higher frequency sides (Table 3), suggesting the coordination of rim of the metal ions through its N3 atom
and amino nitrogen [14]. The bands at 1598 cm
l in the spectrum of free Hm is assigned to the ring vibration
of the imidazolyl group due to the Nl atom. This band in all complexes remains almost unchanged. Thus it
may be concluded that in all these mixed complexes the Hm behaves as bidentate ligand coordinating to the
central ion through its N3 atom and amino nitrogen. There are several possible binding sites in 5FU viz.
C2=O, C4=O, Nl-H and N3-H groups. Table 3 shows significant change in the frequency ofvN3-H band in the
complexes indicating that N3-H group takes part in coordination with metal ions in complex formation. In all
complexes, a medium to strong metal-nitrogen stretching band appears in the range 242-260 cm
"l [15, 16],
indicating six coordination number around these metal ions. All of the mixed complexes exhibit vO-H (aquo)
bands at 3500-3250 cm
l suggesting the presence of water molecules in the complexes [17]. The presence of
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vM-O (aquo) band in lower region of infrared spectrum and absence of HOH bending bands due to lattice
water in 1630-1600 cm
1 region favour the coordinated nature ofwater molecules in these complexes 18].
Table 3. Relevant infrared data for ligands and their mixed complexes (Cm1)
Band Assignment
vO-H
vN-H
vN-H
xtNH+3
vC=C in phase
vC=C of imidazole
(N1)ring
vC=C of imidazole
(N3)ring
6N3-H
Ring breathing for
amino nitrogen
vC-N
vM-O(aquo)
vM-N
Histamine 5FU
3310m
3110w,b
1596s,b
3160m
1570m
1252s
1036s,b
1430s
Co(II) Ni(II) Cu(II) Zn(II) Cd(II)
3410w 3415w 3420w 3338w 3440w
3330m 3328m 3290m 3260w 3338w
3142w 3145w 3180w 3185w 3140w
3135w 3130w 3130w 3137m 3130w
1605s 1595m 1592s 1598s 1590s
1555m 1546m 1555w 1550w 1540s
1426w 1436m 1436m 1422w 1435s
1274m 1273w 1275m 1266s 1270m
1054m 1024m 1018m 1020w 1054s
408m 408m 474m 368m 355m
260m 260m 258m 242w 245m
Electronic spectral and Magnetic studies
The magnetic moments of Cu(II) complex (Table 4) shows the presence of one unpaired electron. The d-d
transition bands appearing in the region 600-900 nm for Cu(II) complex, favours distorted octahedral
geometry around Cu(II) ion in the complex [19]. As reported in the literature that Co(II) high spin octahedral
complexes have magnetic moment ranging from 4.7 to 5.2 B.M. and tetrahedral complexes have magnetic
moment range 4.4 to 4.8 B.M. whereas Ni(II) octahedral complexes have magnetic moment 2.9 to 3.4 B.M.
and tetrahedral complexes have magnetic moment 3.5 to 4.2 B.M. [20]. The laeff values and position of
electronic spectral bands of present Co(II) and Ni(II) complexes as shown in Table 4 suggest octahedral
geometry for Co(II)-5FU-Hm and Ni(II)-5FU-Hm complexes 19, 21 ].
Table4.Solid slale "1- declronic and momdala(305_5K)ofmelalconplexes.
Complexes .max (nm) laefr (B.M.)
Co(5FU)(Hm)(OH).2H20 550, 830 4.95
Ni(5FU)(Hm)(OH).2H20 395, 670 3.21
Cu(5FU)(Hm)(OH).2H20 610 2.01
X-ray diffraction studies
X-ray diffraction data (Table 5) of the complexes were indexed according to the method of Ito [22]. The
indexing pattern yields the lattice constants a 7.32 /It, b 7.01 A, and c 6.79 A for Zn(II) complex
indicating orthorhombic symmetry for this complex.
On the basis of above spectroscopic studies, the octahedral structure has been proposed for all these
complexes.
Antitumour activity studies
It has been observed that the ligand 5FU has significant antitumour activity with T/C value 136 at 12.5, 150
at 25.0 and 154 at 50.0 mg/kg body weight against Dalton’s lymphoma tumour system. Among the ternary
complexes of histamine, Co(II)-5FU-Hm and Zn(II)-5FU-Hm have pronounced antitumour activity with T/C
values more than 125 at all the reported doses (Table 6). All the experimental mice treated with Zn(II)-5FU-
Hm complex survived beyond six month at the dose of 50.0 mg&g body weight. The other compounds are
not effective against Dalton’s lymphoma tumour system at these doses. The Table 7 shows the result obtained
341Udai P. Singh et aL Metal-5-Fluorouracil-Histamine Complexes:
Solution, Structural andAntitumor Studies
for antitumour activity for 5FU and its mixed complexes against sarcoma-180 test system in vivo. As shown
in the Table 7, Co(II)-SFU-Hm and Zn(II)-SFU-Hm exhibit significant antitumour activity, having a T/C
value >125 at all these reported doses. Similar results have been inferred regarding the significant therapeutic
effect ofthe tested compounds from their% ILS values as shown in Table 6 and 7.
Table 5. X-Ray data ofthe complexes
Powder 20 dvues Relative Qce) Q(obs.) hkl
Pattern line Intensity
1. 2. 3. 4. 5. 6. 7.
Co(5FU)(Hm)(OH).2H20
Amorphous
Ni(SFU)(Hm)(OH).2H20
Amorphous
Cu(5FO)(Hm)(On).2n20
Amorphous
Zn(5FU)(Hm)(OH).2H20
1. 12.089 7.3212 164 0.0186 0.0186
2. 12.631 7.0079 294 0.0203 0.0203
3. 13.026 6.7963 402 0.0216 0.0216
4. 21.391 4.1538 346 0.0579 0.0592
5. 22.451 3.9601 100 0.0637 0.0618
6. 25.003 3.5614 102 0.0788 0.0774
7. 26.227 3.3978 225 0.0866 0.0851
8. 27.800 3.2090 168 0.0971 0.0977
9. 29.153 3.0631 72 0.1065 0.1080
10. 30.938 2.8903 247 0.1197 0.1210
11. 31.555 2.8352 101 0.1244 0.1253
12. 33.309 2.6898 82 0.1382 0.1387
13. 34.331 2.6120 88 0.1465 0.1473
14. 34.839 2.5751 102 0.1508 0.1522
15. 37.367 2.4065 95 0.1726 0.1728
16. 38.351 2.3470 87 0.1815 0.1823
17. 42.404 2.1316 100 0.2200 0.2199
18 46.623 1.9480 47 0.2635 0.2640
Cd(5FU)(Hm)(OH).2H20
Amorphous
100
010
001
120
102
301
013
311
OO5
222
114
250
034
620
008
171
290
364
Ligand 5FU and its mixed complexes were also tested for their inhibitory effect on 3H-thymidine
incorporation in Dalton’s lymphoma, Sarcoma-180 and L-929 tumour cell in vitro at 51ag/ml, 10tag/ml and
201ag/ml doses. It is observed that most of those compounds which caused inhibition of 3H-thymidine
incorporation with Dalton’s lymphoma, Sarcoma-180 and L-929 tumour cells, also showed antitumour
activity in vitro (Table 8). The other compounds which were found ineffective antitumour agent in vivo were
also tested but they were found to have no inhibitory effects in vitro also, hence their results are not shown in
the Table 8. It is evident from results obtained in vitro that there is a dose dependent inhibition of 3H-
thymidine incorporation, 20 lag/ml doses of most of the compound was found to be most effective. The
mechanism of antitumour action of these compounds is not well known. The present results suggest that the
antitumour properties of these compounds may be due to their inhibitory action on the replication of DNA in
tumour cells.
EXPERIMENTAL
Material and Methods
All chemicals were used of analytical grade. The metal nitrates used were from E. Merck grade. 5FU and
histamine were obtained from Aldrich and Sigma Chemical Co. U.S.A respectively. 3H-Thymidine was
obtained from Bhabha Atomic Research Centre, Mumbai, India. The tissue culture medium RPMI-1640 and
the other reagents were purchased from Sigma Chemical Company (St. Louis, Mo. USA). All culture media
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were supplemented with 20 [ag/mL gentamycin, 100 lxg/mL streptomycin, 100 lxg/mL penicillin and 10%
heat-inactivated fetal calf serum (Biological Industries, Haemak, Israel). All test compounds were suspended
in phosphate buffered saline solution (PBS) (pH 7.0).
Table 6. Screening data ofmixed ligand complexes for antitumour activity against Dalton’s lymphoma in
vivo
Compounds
5FU
Co(5FU)(Hm)(OH).2H20
Ni(5FU)(Hm)(OH).2H20
Cu(5FU)(Hm)(OH).2H20
Zn(5FU)(Hm)(OH).2H20
Cd(5FU)(Hm)(OH).2H20
Dosage ip Mean Lifespan No. ofmice T/C % % ILS
injection mg/kg ofnon survivors Surviving
body weight
a T/C (days)
b >6 months
12.5 30/22 136.36 36.36
25.0 33/22 150.00 50.00
50.0 34/22 154.54 54.54
12.5 38/22 172.72 72.72
25.0 35/22 159.09 59.09
50.0 36/22 163.36 63.63
12.5 25/22 113.63 13.63
25.0 20/22 90.90
50.0 24/22 109.09 09.09
12.5 16/22 72.72
25.0 08/22 36.36
50.0 13/22 59.09
12.5 35/22 159.09 59.09
25.0 33/22 150.00 50.00
50.0 all alive 6(100)
12.5 19/22 86.36
25.0 14/22 63.63
50.0 03/22 13.63
T tumoured, C control; ILS increased lifespan
aA single ip injection ofthe reported dose was given to six mice in each experiment.
bin calculating average survival time, mice surviving >6 months were not included.
Table 7. Screening data of mixed ligand complexes for antitumour activity against
Sarcoma-180 in vivo
Compounds
5FU
Co(5FU)(Hm)(OH).2H20
Ni(SFU)(Hm)(OH).2HzO
Cu(5FU)(Hm)(OH).2HzO
Zn(5FU)(Hm)(OH).2HzO
Cd(5FU)(Hm)(OH).2HO
Dosage ip Mean Lifespan No. ofmice T/C
injectionm,gkg ofnon survivors Surviving %
body weight T/C (days)
b >6 months
12.5 13/7 185.7
25.0 11/7 157.1
50.0 all alive 6(100)
12.5 10/7 142.8
25.0 12/7 171.4
50.0 18/7 257.1
12.5 08/7 114.2
25.0 06/7 85.7
50.0 05/7 71.4
12.5 07/7 100.0
25.0 08/7 114.2
50.0 06/7 85.7
12.5 17/7 242.8
25.0 10/7 142.8
50.0 13/7 185.7
12.5 04/7 57.1
25.0 03/7 42.8
50.0 02/7 28.5
% ILS
85.7
57.1
42.8
71.4
157.1
14.2
14.2
142.8
42.8
85.7
T tumoured, C control; ILS increased lifespan
aA single ip injection ofthe reported dose was given to six mice in each experiment.
bin calculating average survival time, mice surviving >6 months were not included.
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Table 8. Percentage inhibition of 3H-Thymidine incorporation in Dalton’s lymphoma,
Sarcoma-180 and L-929 Tumor Cell in vitro*
Compound
Dose
5tag/ml 10tag/ml 201xg/ml
Co(5FU)(Hm)(OH).2H20
Zn(5FU)(Hm)(OH).2H20
DL
50.36 48.04 29.02
92.15 93.24 95.28
S-l$0
5FU 47.36 48.08 57.80
Co(5FU)(Hm)(OH).2H20 23.75 50.65 92.29
Zn(5FU)(Hm)(OH).2H20 36.32 54.79 85.85
L-929
5FU 18.33 49.93
Co(5FU)(Hm)(OH).2H_O 64.71 65.53
Zn(5FU)(Hm)(OH).2H20 30.27 32.15
*This table shows the results obtained for the compounds which show significant inhibition.
Potentiometric pH Titration
Solutions of Co(II), Ni(II), Cu(II), Zn(II) and Cd(II) nitrates were prepared in double distilled water and
standardized by EDTA titration method [23]. Ligand solutions of 0.01 M 5FU and 0.01 M Hm were also
prepared in double distilled water. Stocks solutions of sodium nitrate (1.0 M) and standard nitric acid (0.02
M) were used. Carbonate-free NaOH (0.2 M) solution was standardized against oxalic acid solution and used
as titrant.
All the measurements were carried out at 25 + 0.1C using Schott CG841 pH-meter. The six mixtures A, B,
C, D, E and F were prepared and titrated separately against 0.2 M NaOH (COz-free) bubbling N2 in the cell
during the titration" (A) HNO3 (0.02 M, 5.0 ml) + NaNO3 (1.0 M, 5.0 ml) + water; (B) HNO3 (0.02 M, 5.0
ml) + NaNO3 (1.0 M, 5.0 ml) + 5FU (0.01 M, 5.0 ml) + water; (C) HNO3 (0.02 M, 5.0 ml) + NaNO3 (1.0 M,
5.0 ml) + 5FU (0.01 M, 5.0 ml) + metal solution (0.01 M, 5.0 ml) + water; (D) HNO3 (0.02 M, 10.0 ml) +
NaNO3 (1.0 M, 5.0 ml) + Hm (0.01 M, 5.0 ml) + water; (E) HNO3 (0.02 M, 10.0 ml) + NaNO3 (1.0 M, 5.0
ml) + Hm (0.01 M, 5.0 ml) + metal solution (0.01 M, 5.0 ml) + water; (F) HNO3 (0.02 M, 10.0 ml) + NaNO3
(1.0 M, 5.0 ml) + 5FU (0.01 M, 5.0 ml) + metal solution (0.01 M, 5.0 ml) + Hm (0.01 M, 5.0 ml) + water. In
each case, the total volume was maintained at 50.0 ml and ionic strength 0.1 M (NaNO3).
Preparation of the complexes
Solution of (lm mole) metal nitrates in 15 ml ethanol and 5FU (lm mole) in 30 ml ethanol were obtained by
heating. Both the warm solutions were mixed and the volume of the resultant mixture was reduced to about
50% by heating with constant stirring. The precipitates were obtained at- pH 8 by adding aqueous sodium
hydroxide solution. Keeping the precipitates in an ice bath and on adding an aqueous solution of (lm mole)
histamine to it, a clear solution was obtained. The solid complexes were obtained by concentrating the above
solution at 60 C to 5 ml and on adding diethyl ether. The precipitate was filtered washed with absolute
ethanol several times, finally with anhydrous diethyl ether and dried at- 50 C.
The analysis of C, H and N were carried on Perkin-Elmer model 240C elemental analyzer. The metal ions
were determined by dissolving the complexes in dilute nitric acid and titrating against EDTA [23]. The
infrared spectra of the complexes were registered on a Perkin-Elmer 783 spectrophotometer. The electronic
spectra of complexes were registered in the solid state with a Perkin-Elmer Lambda 35 UV/VIS
spectrophotometer in the range of 200-1100 nm. Magnetic susceptibility measurements at 305.5 K were done
by Faraday magnetic susceptibility balance and X-ray powder data were obtained on Philips PW 1710
diffractometer using Cu-Ka radiation.
Antitumor activity evaluation
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The antitumour activity both in vivo and in vitro of the mixed ligand complexes has been evaluated according
to the method reported elsewhere [24]. The antitumour response was also measured as median survival time
(days) in which median life span was determined and the percentage of increased life span (ILS) was
calculated as
median survival time (days) oftreated group
%oflLS= ( -1) xl00
median survival time (days) of control group
According to the National Cancer Institute [25], the criterion for a significant therapeutic effect is >_ 30 % ILS
for P388 leukemia (ip).
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